- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03729180
O estudo ImPreSS: Tomada de decisões farmacogenômicas no momento da cirurgia
O ImPreSS Trial: Implementação de Apoio à Decisão Farmacogenômica Point-of-Care em Cuidados Perioperatórios
The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago.
At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS).
Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients.
There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase
After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Cancer Clinical Trials Office
- Número de telefone: 1-855-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University Of Chicago Medicine Comprehensive Cancer Center
-
Contato:
- Emily Schierer
- Número de telefone: 773-753-1200
- E-mail: theimpresstrial@uchicago.edu
-
Investigador principal:
- Peter O'Donnell, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult patients who have planned elective surgical procedures at the University of Chicago
- Must be aged 18 years or older
Exclusion Criteria:
- Patients who have undergone, or are being actively considered for, liver or kidney transplantation
- Patients with known active or prior leukemia.
- Inability to understand and give informed consent to participate.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Pain Cohort
Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events. |
Participants will be undergoing routine planned surgeries. Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes. |
|
Experimental: Pharmacogenomic (PGx) Arm [Randomization Arm 1]
All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers. |
Participants will be undergoing routine planned surgeries. Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes. |
|
Outro: Control Arm [Randomization Arm 2]
All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group. |
Participants will be undergoing routine planned surgeries. Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.
Prazo: 5 years
|
To explore the feasibility and utility of implementing broad preemptive pharmacogenomic testing in the perioperative setting by determining the frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period. |
5 years
|
|
Rate of use of high-risk drugs in perioperative setting
Prazo: 5 years
|
To determine the rate of use high-risk drugs (red or yellow pharmacogenomic risk) in the group of patients for whom pharmacogenomic results are available compared to their rate of use (without provider knowledge of pharmacogenomic risk designation) in the control arm. |
5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of use of favorable drugs in perioperative setting
Prazo: 5 years
|
To determine the occurrence of specific pharmacogenomically-informed adverse drug events in both arms. |
5 years
|
|
Occurrence of specific pharmacogenomically-informed adverse drug events
Prazo: 5 years
|
To determine the occurrence of specific pharmacogenomically-informed adverse drug events in both arms. |
5 years
|
|
Pharmacogenomic result availability on pain management services in both arms using a research database for each patient
Prazo: 5 years
|
To explore the effects of pharmacogenomic result availability on pain management services in both arms. |
5 years
|
|
Comparison of pain scores on a 10 point scale
Prazo: 5 years
|
To compare pain scores between both arms. |
5 years
|
|
Anesthesia and critical care providers knowledge and perceptions of prescribing decisions using a information provided in research database
Prazo: 5 years
|
To determine anesthesia and critical care providers' knowledge and perceptions of prescribing decisions in order to develop better genomic delivery systems in the future |
5 years
|
|
Differences in patient reported satisfaction using research database
Prazo: 5 years
|
To determine whether differences in patient-reported satisfaction and adherence likelihood are observable for patients whose providers access and use pharmacogenomic information. |
5 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Peter O'Donnell, University of Chicago
Publicações e links úteis
Publicações Gerais
- Truong TM, Apfelbaum JL, Danahey K, Schierer E, Ludwig J, George D, House L, Karrison T, Shahul S, Anitescu M, Choksi A, Hartman S, Knoebel RW, van Wijk XMR, Yeo KJ, Meltzer DO, Ratain MJ, O'Donnell PH. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 Nov 1;135(5):929-940. doi: 10.1213/ANE.0000000000005951. Epub 2022 Feb 25.
- Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, Shahul S, Anitescu M, Gerlach R, Knoebel RW, Meltzer DO, Ratain MJ, O'Donnell PH. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 Apr 1;32(3):79-86. doi: 10.1097/FPC.0000000000000455.
- Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PH. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 Dec;106(6):1179-1183. doi: 10.1002/cpt.1567. Epub 2019 Aug 21. No abstract available.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Serviços de Saúde
- Instalações de saúde Força e serviços de trabalho
- Serviços de Saúde Preventiva
- Técnicas genéticas
- Serviços genéticos
- Serviços de diagnóstico
- Teste genético
- Testes hematológicos
Outros números de identificação do estudo
- IRB17-1422
- 1R01HG009938 (Concessão/Contrato do NIH dos EUA)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .